Industry Recognition Yangtze River Pharmaceutical Group Wins the 2021 EFQM Global Award

The Chinese company Yangtze River Pharmaceutical (Group) Co. became one of the 12 organizations to win the EFQM Global Award this year. It is also the first pharmaceutical company in the world to receive the award after the implementation of the new EFQM model in 2019.

Related Vendors

AZO GmbH + Co. KG

Italvacuum, Srl

MG2 s.r.l.

Jiangsu/China – On March 4, 2021, Yangtze River Pharmaceutical (Group) Co. became one of the 12 organizations to win the EFQM Global Award, one of the three major quality awards in the world. The objective of the award is to recognize outstanding organizations worldwide that demonstrate an indisputable track record of success in turning strategy into action and the continuous improvement of their performance. Moreover, Yangtze River Pharmaceutical Group is the first pharmaceutical company in the world to receive the award after the implementation of the new EFQM model in 2019. “This award is the result of our continuous learning, organizational changes and performance improvement, indicating that the company's management level has been aligned with the management level of world-class companies,” says Xu Jingren, chairman of Yangtze River Pharmaceutical Group.

China’s Largest Drug Manufacturer Celebrates its 50th Anniversary

In January 2021, eight experts from different countries including Germany and Austria formed a review panel to conduct a 5-day assessment consisting of on-site visits and online interviews. In their feedback, they pointed out that Yangtze River Pharmaceutical Group has established a distinctive development concept, and its corporate culture is deeply rooted in the hearts of people. The company, which is also celebrating its 50th anniversary this year, has grown to become the largest drug manufacturer in China with more than 16,000 employees. Its focus is on both R&D and the production of traditional Chinese as well as chemical medicines. In parallel to expanding its international market activities, Yangtze River Pharmaceutical Group has continuously extended its business scope, involving biological drugs, medical equipment, and health food.

Gallery

Gallery with 5 images

European Technology from Syntegon Contributes to Success

Among the equipment that contributes to this success is a substantial number from Germany-based Syntegon Technology. “Syntegon’s machines fulfill GMP requirements sophisticatedly. They integrate their global experience in an advanced equipment design, which provides a strong guarantee for the quality of our pharmaceutical products,” says You, equipment director at Yangtze River Pharmaceutical Group. Amongst others, the pharmaceutical manufacturer uses FLC lines from Syntegon for liquid fill-finish operations and fills pharmaceutical powders with AFG machines. GKF capsule filling machines are used for Oral Solid Dosage (OSD) forms, while CUK cartoning machines ensure safe secondary packaging. “We are very proud to contribute to this ongoing success of our customer and look forward to further joint projects,” says Dr. Jerome Freissmuth, vice president international sales pharma at Syntegon.

An Important Milestone

“The award is even more important in the context of the China-EU Comprehensive Agreement on Investment (CAI),” Xu Jingren says. “In my opinion this is a fusion of Chinese and European culture and quality. It is also an important milestone in the development of our company: the award will make more people around the world familiar with the high quality of Chinese pharmaceutical manufacturing, especially at Yangtze River Pharmaceutical Group. We will continue to apply the EFQM model to serve the health of all mankind.”

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

(ID:47264706)